Neoadjuvant Therapy in Differentiated Thyroid Cancer
International Journal of Surgical Oncology · 2016 · 2016 · 1-8
DOI: 10.1155/2016/3743420 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Surgical Oncology, 2016. Verfasst von Rajan P Dang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Invasion of differentiated thyroid cancer (DTC) into surrounding structures can lead to morbid procedures such as laryngectomy and tracheal resection. In these patients, there is a potential role for neoadjuvant therapy.
Methods
We identified three studies involving the treatment of DTC with neoadjuvant chemotherapy: two from Slovenia and one from Japan.
Results
These studies demonstrate that in selected situations, neoadjuvant chemotherapy can have a good response and allow for a more complete surgical resection, the treatment of DTC. Additionally, the SELECT trial shows that the targeted therapy lenvatinib is effective in the treatment of DTC and could be useful as neoadjuvant therapy for this disease due to its short time to response. Pazopanib has also demonstrated promise in phase II data.
Conclusions
Thus, chemotherapy in the neoadjuvant setting could possibly be useful for managing advanced DTC. Additionally, some of the new tyrosine kinase inhibitors (TKIs) hold promise for use in the neoadjuvant setting in DTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Hematology-Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID-Profile: Rajan P Dang, Daniel McFarland
Zitieren
APA
Dang, R. P., McFarland, D., Le, V. H., Camille, N., Miles, B. A., Teng, M. S., Genden, E. M., & Misiukiewicz, K. J. (2016). Neoadjuvant Therapy in Differentiated Thyroid Cancer. International Journal of Surgical Oncology, 2016, 1-8. https://doi.org/10.1155/2016/3743420
Vancouver
Dang RP, McFarland D, Le VH, Camille N, Miles BA, Teng MS, et al. Neoadjuvant Therapy in Differentiated Thyroid Cancer. International Journal of Surgical Oncology. 2016;2016:1-8. doi:10.1155/2016/3743420
BibTeX
@article{Dang2016,
author = {Dang, Rajan P and McFarland, Daniel and Le, Valerie H and Camille, Nadia and Miles, Brett A and Teng, Marita S and Genden, Eric M and Misiukiewicz, Krzysztof J},
title = {Neoadjuvant Therapy in Differentiated Thyroid Cancer},
journal = {International Journal of Surgical Oncology},
year = {2016},
volume = {2016},
pages = {1--8},
doi = {10.1155/2016/3743420}
}
EUVIMED